TScan Therapeutics, Inc. (TCRX) stock
TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)
Close on Nov 17, 2026Market cap $10.23MP/E –Yield –
TScan Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
TScan Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -1655.4%. For fiscal 2025 it was -1256.8%, against -4527.7% the year before. The highest annual figure on record is -423.9% in fiscal 2023.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1256.8% | +3270.8 |
| FY2024 | Dec 31, 2024 | -4527.7% | −4103.8 |
| FY2023 | Dec 31, 2023 | -423.9% | +65.4 |
| FY2022 | Dec 31, 2022 | -489.3% | −9.8 |
| FY2021 | Dec 31, 2021 | -479.5% | +1928.5 |
| FY2020 | Dec 31, 2020 | -2408.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -2888.6% | −1687.3 |
| Q1 FY2026 | Mar 31, 2026 | -2919.1% | −1347.2 |
| Q4 FY2025 | Dec 31, 2025 | -895.1% | +4489.7 |
| Q3 FY2025 | Sep 30, 2025 | -1422.1% | +1427.0 |
| Q2 FY2025 | Jun 30, 2025 | -1201.3% | +4705.6 |
| Q1 FY2025 | Mar 31, 2025 | -1571.9% | +3753.5 |
| Q4 FY2024 | Dec 31, 2024 | -5384.8% | −5112.8 |
| Q3 FY2024 | Sep 30, 2024 | -2849.1% | −2257.5 |
| Q2 FY2024 | Jun 30, 2024 | -5906.9% | −5143.1 |
| Q1 FY2024 | Mar 31, 2024 | -5325.4% | −4993.8 |
| Q4 FY2023 | Dec 31, 2023 | -272.0% | +333.0 |
| Q3 FY2023 | Sep 30, 2023 | -591.6% | −108.6 |
| Q2 FY2023 | Jun 30, 2023 | -763.8% | −391.6 |
| Q1 FY2023 | Mar 31, 2023 | -331.7% | +203.1 |
| Q4 FY2022 | Dec 31, 2022 | -604.9% | −107.4 |
| Q3 FY2022 | Sep 30, 2022 | -483.1% | +173.6 |
| Q2 FY2022 | Jun 30, 2022 | -372.2% | +2.6 |
| Q1 FY2022 | Mar 31, 2022 | -534.8% | −144.5 |
| Q4 FY2021 | Dec 31, 2021 | -497.5% | +484.5 |
| Q3 FY2021 | Sep 30, 2021 | -656.7% | +1815.7 |
| Q2 FY2021 | Jun 30, 2021 | -374.8% | – |
| Q1 FY2021 | Mar 31, 2021 | -390.3% | – |
| Q4 FY2020 | Dec 31, 2020 | -982.0% | – |
| Q3 FY2020 | Sep 30, 2020 | -2472.4% | – |
See a number that looks wrong?